United States Patent 1191 Cornfeld [451 Nov. 11, 1975 [5 1 TAMPONS IMPREGNATED WITH 3.108.043 10/1963 Somerville 128/270 I CONTRACEPTIVE COMPOSITIONS 3.108043 10/1963 Mi11man 128/270 X 3,424,159 1/1969 Whitehead at 211.... 128/263 1 Inventorl Edward Potomac, 3.490.454 1/1970 G01df2ll'b et a1 128/285 3.521637 7/1970 Waterbury 1 128/270 [73] Asslgnee' ai S'lver Spnng 3.639562 2/1972 Gordon et Z11..... 128/270 x 3,679,102 7/1972 Charle 1 1 128/260 X [22] i Aug 1 974 3,749,094 7/1973 Duncan 128/270 3,756,238 9/1973 Hanke.... 128/270 [21] Appl. No: 493,831 3,850,173 11/1974 Dash 128/261 152 US. Cl. 128/270; 128/260; 128/263 i' Medbery 424/16 Attorney, Agent, or Firm-Sherman & Shalloway [51] Int. Cl. A61F 13/20; A61K 7/00 [58] Field of Search 128/260, 270, 285, 290 R, [57] ABSTRACT 261; 424/16 45 Vaginal sponges and/or tampons impregnated with contraceptive compositions and methods of prevent- [56] References Clted ing conception or implantation by insertion in an ani- UNITED STATES PATENTS mal organism of said sponge or tampon prior to expo- 702,570 6/1902 Lohlein 128/263 sure to conception. 2,943,979 7/1960 Elias 424/16 3.091.241 5/1963 K6116 128/270 3 Clams, 5 Drawlng Figures US. Patent Nov. 11, 1975 FIG.4
FIGJ
FIG.5
TAMPONS IMPREGNATED WITH CONTRACEPTIVE COMPOSITIONS BACKGROUND OF THE INVENTION DESCRIPTION OF THE PRIOR ART It has long been an object of the pharmaceutical industry to discover a safe and'effective method of preventing conception which can be utilized precoitus that is non-interfering and easy to use.
Heretofore, it has been known to impregnate tampons with an abortive facient, such as pi'ostaglandin, in order to terminate a conception in the very early states of the pregnancy.
Additionally, prior art methods are known for preventing conception by utilization of vaginal foams or creams containing cont'faceptive compositions. The prior art means of preventing conception are either inconvenient to use or have physiological or psychological drawbacks once pregnancy has begun.
U.S. Pat. No. 3,105,128 shows a method of microencapsulation.
U.S. Pat. No. 3,691,271 shows a sanitary napkin with microcapsules filled with a bactericidal and fungicidal deodorant.
U.S. Pat. No. 3,814,809 shows the combination of a suppository and tampon with a contraceptive drug for use after exposure.
I SUMMARY OF THE PRESENT INVENTION It is a general feature of the present invention to avoid and overcome the foregoing and other difficulties and objections to prior art contraceptive means by the provision of a more effective and generally acceptable means. More specifically, a feature of the present invention is to provide a vaginal sponge or tampon which is impregnated with a known safe and effective contra ceptive composition.
Further, another feature of the present invention is to provide a vaginal sponge or tampon which is impregnated with a contraceptive drug that is microencapsulated so that there is a sustained release of the contraceptive composition before, during and/or after coitus.
It is still another feature of the present invention to provide a means for insertion of the sponge or tampon into the vagina which can be packaged as a single unit.
A yet further feature of the present invention is to provide a means for housing the impregnated sponge or tampon, inserting the sponge or tampon and, if desired, removing the sponge or tampon from the vagina.
The aforesaid features of the present invention, and other features which will become apparent as the description proceeds, are accomplished by providing a vaginal sponge or tampon that is impregnatedupreferably 'a microencaptlital eenrrlce snve cameos:
' sules which maybe used are those which provide a sustained release and/or those which are pressure rupturable. The contraceptive composition may include any of the known steroidal or non-steroidal compounds.
A method having certain features of this invention includesthe step of inserting and maintaining in the vagina a sponge or tampon impregnated with a contraceptive composition, preferably a composition which is microencapsulated.
DETAILED DESCRIPTION OF THE PRESENT INVENTION For a better understanding of the present invention, reference should be made to the accompanying drawings,. wherein like numerals indicate similar parts throughout the several views and wherein:
FIG. 1 isa perspective view of a tampon and applicator inaccordance with this invention. I
FIG. 2 isa perspective view of a further applicator and tampon of the present invention.
FIG. 3 is a perspective view of a tampon of this invention. p
FIG. 4 is a cross-sectional view of the impregnated tampon of FIG. 3
FIG. 5 is a cross-sectional view of an impregnated sponge having aspring means.
PREFERRED EMBODIMENTS OF THE PRESENT I INVENTION able in thehousing 12 so as to eject thetampon 14 from thehousing 12. If thetampon 14 is provided with a means for removal, such as astring 19, thehousing 12 may be provided with'aslot 18 so as to accommodate the string. V
FIG. 2 illustrates a further embodiment of the invention wherein there is provided anapplicator 20 having ahousing 28 containing animpregnatedtampon 24 in the front end portion. Theapplicator 20 is provided with aplunger 26 which ejects thetampon 24 and is capable of providing a vacuum suction so as to withdraw the tampon when desired. x
FIG. 3 shows the tampon prior to compression and insertion into the applicator shown in FIG. 1. The tampon comprises any of the known cellulosic tampons that are well known in the art. The tampon includes those which contain the conventional polyurethane foams, the reaction product of liquid polyols (polyester or polyether) and a disfunctional isocyanate, usually toluene diisocyanate. A catalyst such as tin, an ammine, a flowing agent, generally water, and foaming stabilizers are also employed. The required cylinders for tampon use are cut from the prepared foam. Thestring 19 is provided for removal of the tampon either preor post-coitus FIG. 4 is a cross-sectional view of the tampon of FIG. 3 showing themicroencapsulations 40 The microcapsules used in the present: invention uahrbe madeabf any Beaver-newly mplayea material in :the mieroefic apwanna new; -Represenmive of polymeric mataria-ls to prcs'anee- @He--mi@f6capsules aresuellz polymfli's an polymyimeehol, pdlyerh ylene, polypropylene. polystyrilefpolyatrylamidesg polyethers; pdlyestehs; polyamides, polybutadiene, polyisoprene, epoxy resins, polyurethanes, ethyl cellulose, carboxymethyl cellulose and the like. The nature and the size of the walls will be generally chosen for their compatibility with the contraceptive composition used. Generally, the ratio of the weight of the wall to the total weight of the filled microcapsule ranges from between 3-10:100.
Any conventional technique of microcapsule fabrication can be used, particularly microencapsulation by mechanical means such as centrifugal microencapsulatioh. In this method, droplets of the material to be microencapsulated are formed by the centrifugal force of a turntable which then traverse by means of the velocity with which they thus acquire a thin film of fluid product designed to form the wall of the microcapsule. Conventional wall-hardening treatment can be employed which, in a case where the wall is prepared from a thermoplastic material, can simply be a sudden cooling of the microcapsules formed. Representative suitable microencapsulation operation can be found in the literature, for instance U.S. Pat. No. 3,015,128.
The material encapsulated in the microcapsules can be, for instance, such contraceptive compounds as nonylphenoxypolyethoxyethanol and an estrongenic compound such as 3-methoxy-19-nor-170z-pregna- 1,3,5( l)-trien-20-yn-17-o1; l9-nor-17oz-pregn-4-enyne-l3B, 17 diol and the like.
FIG. is a cross-sectional view of avaginal sponge 50 which comprises preferably a cellularresilient material 52 having therein aspring 54 for maintaining the sponge in an expanded state. Thesponge 52 may comprise any of the known water-resistant cellular matter such as cellulosic sponge, polyurethane, polyesters, and the like which are compatible with the body. Thesponge 50 contains throughout themicrocapsules 40 containing the contraceptive material. The size and composition of the capsule wall is preferably varied in solubility and rupturability so as to provide a sustained release during usage. Additionally, the microcapsules may contain in addition to the contraceptive compositions any spermicide which is known in the art. The microencapsulation permits the utilization of known compatible compositions simultaneously.
The method in accordance with this invention comprises inserting in the animal organism one vaginal tampon which is impregnated with a contraceptive composition and/or spermicidal composition between one hour and twenty-four hours prior to exposure. As stated above, the contraceptive has a sustained release in the vagina during and after coitus so that any exteriorally inserted fluids, such as semen resulting from coitus, will be exposed to the contraceptive compositions and any accompanying spermicide released by the rupturability and solubility of themicro capsules 40 in the normal muscosa fluid present in the vagina.
Obviously, the dosage form will depend upon the contraceptive composition employed, besides that the microcapsules generally have a size ranging from about 50 1,000 microns in diameter. The thickness of the wall of the microcapsule will vary according to the materials used and to the effect desired,
The microcapsules are introduced either directly into the sponge or tampon at a moment-in which its fluidity porate them before termination of the polymerization of the sponge.
In general, microcapsules are introduced into the sponge or tampon in the course of manufacture in the form of a liquid or suspension; the best possible homogenization is obtained by suitable mixing by agitation, shaking or blowing in of a gas. The density of the liquid or of the suspension is then adjusted to that of the microcapsules by addition of a suitable inert substance. It is also possible to select microcapsules whose density corresponds to that of the liquid or suspension at the time of their introduction into the sponge or tampon. The following non-limiting examples, in which parts and percentages refer to weight, are given by way of illustration and allow a fuller understanding of the present invention.
EXAMPLE 1 Tampon containing a microencapsulated contraceptive composition:
The following contraceptive composition is prepared:
Contraceptive Compound 4.0 Vaseline 6.0 Glycerol 10.0 Anti-ferment 0.1 Water to make-up 100.0
The contraceptive composition is then microencapsulated by the known technique, using polypropylene, the microcapsules having an average diameter of 50-100 microns and preferably 60-80 microns. Microcapsules are dispersed either by a suitable mechanical device or by projection using compressed air or gas.
The contraceptive compound may be any of the known estrogenic agents such as Enovid (Trademark).
EXAMPLE 11 The sponge containing microencapsulated contraceptive composition:
The following solution is prepared:
Glycerin 5.00 Contraceptive Compound 10.00 Oxytoxin 0.50
EXAMPLE 111 The following composition is prepared:
Spermicide 10.00 Gl yrine 10.00 Sodium Lauryl SulfateSolution (30%) 30.00
This composition containing-- the spermicide; is thh microencapsulated utilizing p e lyyiay l 'a uhalfiay any positions, the vaginal sponge or tampon may be surface coated or impregnated with a contraceptive composition dissolved or suspended in a melt of a low-melting, biodegradable wax. The 'wax with the contraceptive compound incorporated is then either powdered or the melt is poured over a cold surface and a waxy material scraped off in the forms of powder or flakes. Among the vehicles for slow release of the contraceptive composition in biological fluids are acetyl palmitate, carbona wax, lauric acid, a mixture of sodium laurate and lauric acid, a mixture of stearic acid and sodium stearate, a mixture of archidonic acid and sodium archidonate and acetyl palmitate.
Obviously, the embodiments shown are exemplary only and a wide variety of embodiments may be devised without departing from the spirit and scope of the invention.
What is claimed is:
l. The method of preventing conception or implantation which comprises inserting into the vagina of a mammal a sponge tampon impregnated with microcapsules having a contraceptive composition prior to exposure to exteriorally inserted fluids and permitting said sponge tampon to remain in the vagina until at least an effective amount of said composition is released and leaving the sponge tampon in the vagina at least during the insertion of said exterior fluids so as to prevent conception or implantation from said fluids.
2. The method of claim 1 wherein said comosition is microencapsulated in a sustained release form and said composition is caused to be released by the biological muscosa fluid.
3. The method of claim 1 wherein said microcapsules include a spermicide and said spermicide is released with said contraceptive composition.